We introduce a diagnostic biomarker for amyotrophic lateral sclerosis that distinguishes it from similar conditions by examining a combination of plasma proteins. This innovation also offers insights into the underlying mechanisms of the disease, highlighting a compensatory process in skeletal muscle and bioenergetics that seems to start much earlier than previously thought.